FAPI诊疗一体化在晚期喉鳞癌中的应用:99mTc-FAPI-46 SPECT/CT引导177Lu-FAPI-2286治疗
一例47岁晚期喉鳞状细胞癌男性患者,化疗后骨显像发现广泛骨转移,99mTc-FAPI-46 SPECT/CT显示原发喉部肿瘤、颈部软组织受累及广泛骨转移的FAPI摄取,准确反映整体疾病负荷;因化疗后进展并需骨痛姑息治疗,患者入组临床试验接受177Lu-FAPI-2286放射性配体治疗,治疗后显像证实示踪剂在全部已知病灶聚集。
要点
- 99mTc-FAPI-46 SPECT/CT可显示晚期喉鳞癌原发灶、颈部软组织及骨转移的FAPI摄取。
- FAPI显像所见的摄取分布准确反映了整体疾病负荷。
- 177Lu-FAPI-2286治疗后显像证实示踪剂在全部已知病灶聚集。
核心结论
- FAPI显像和治疗在晚期喉鳞癌中具有诊疗一体化潜力。
研究设计与样本
- 一例47岁晚期喉鳞状细胞癌男性患者的个案报告。
主要发现
- 99mTc-FAPI-46 SPECT/CT显示原发喉部肿瘤、颈部软组织受累及广泛骨转移的FAPI摄取。
- 治疗后显像证实177Lu-FAPI-2286在全部已知病灶聚集。
临床怎么用
- 对化疗后进展且伴骨痛的晚期喉鳞癌患者,可考虑FAPI显像评估疾病负荷并探索FAPI靶向放射性配体治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 47-year-old man with advanced laryngeal squamous cell carcinoma had received chemotherapy but subsequently developed widespread skeletal metastases identified on bone scintigraphy. He underwent 99m Tc-FAPI-46 SPECT/CT, which demonstrated FAPI uptake in primary laryngeal tumor, cervical soft tissue involvement, and extensive skeletal metastases, accurately reflecting the overall disease burden. Due to disease progression despite chemotherapy and for palliative management of bone pain, he was enrolled in a clinical trial and received 177 Lu-FAPI-2286 radioligand therapy. Post-treatment imaging confirmed tracer accumulation in all known disease sites, highlighting the clinical utility of FAPI-based imaging and its theranostic potential in advanced laryngeal carcinoma.
引用
- Elahifard H, Samadi MH, Saberifar M, et al. Theranostic Application of FAPI in Advanced Laryngeal Squamous Cell Carcinoma: 99m Tc-FAPI-46 SPECT/CT Guided 177 Lu-FAPI-2286 Therapy. Clin Nucl Med. 2026. PMID: 42149939. doi:10.1097/RLU.0000000000006505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。